What is the potential for bleeding when using NOACs?
Despite low-dose NOACs, such as dabigatran 110 mg or rivaroxaban 15 mg/10 mg, being more commonly used than standard-dose NOACs (dabigatran 150 mg or rivaroxaban 20 mg), the use of NOACs was associated with reduced risk of ischemic stroke or systemic embolization, major bleeding, ICH, and total mortality compared with warfarin. However, serious bleeding still occurs and the potential for bleeding often discourages initiation of anticoagulant therapy in patients deemed to be at high risk of bleeding.